Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 121 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Streptococcus Pneumoniae Infection Clear all

Conditions: Community-Acquired Pneumonia (CAP)
Interventions: Receipt of PCV20; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 19 Years and older
Enrollment: 846,279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumococcal Infection
Interventions: V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1), PCV20 (Stage 2); Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 2 Months to 15 Months
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Madera, California • Miami, Florida • Tampa, Florida + 12 more

Conditions: HIV, Pneumonia, Infections, Pneumococcal
Interventions: Vaccine Administration; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 350,399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia
Interventions: PCV7, Prevnar®, Pneumovax 23; Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 70 Years to 79 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
Interventions: 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 27
States / cities: Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more

Conditions: Pneumococcal Infections
Interventions: Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 50 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pneumococcal Disease
Interventions: 31 valent pneumococcal conjugate vaccine, PCV20, PCV21; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,049 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more

Conditions: Malignancy, Cancer, Hematological Malignancies, Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor
Interventions: Commercial CAR-T, Investigational CAR-T; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions: 13-valent Pneumococcal Conjugate Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 5 Years
Enrollment: 373 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more

Conditions: Pneumococcal Infection
Interventions: 23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine; Biological
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 50 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,515 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more

Conditions: Pneumococcal Infections
Interventions: PCV7 + PPV23, 2 months, PCV7 + PPV23, 6 months; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 55 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Pneumococcal Infection
Interventions: PNEUMOVAX, Prevnar; Biological
Lead sponsor: Emory University; Other
Eligibility: 25 Years to 89 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Decatur, Georgia

Conditions: Pneumococcal Infection
Interventions: Placebo, PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Rochester, New York • Cincinnati, Ohio

Conditions: Pneumococcal Infections, Streptococcus Pneumoniae, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 3 Months
Enrollment: 368 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 10
States / cities: Birmingham, Alabama • Palo Alto, California • Miami, Florida + 6 more

Conditions: Pneumococcal Infections
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chinle, Fort Defiance, Whiteriver, AZ; Gallup, Shiprock, NM, Arizona

Conditions: HIV Infections, Pneumococcal Infections
Interventions: 13-valent pneumococcal conjugate vaccine, Blood draw; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Pneumococcal Infections
Interventions: 13 valent Pneumococcal Conjugate Vaccine, 23vPS; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 70 Years and older
Enrollment: 938 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 51
States / cities: Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more

Conditions: Streptococcus Pneumoniae
Interventions: pneumoniae bacteremia therapy; Drug
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pneumococcal Infection
Interventions: V116, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Madera, California + 23 more

Conditions: Pneumococcal Infections
Interventions: Multivalent, Prevnar 13, PPSV23, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years to 64 Years
Enrollment: 444 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 14
States / cities: Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 12 Months
Enrollment: 1,664 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 87
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more

Conditions: Acute Otitis Media, Mastoiditis
Interventions: No intervention; Other
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more

Conditions: Pneumococcal Disease
Interventions: V116, Placebo, PCV15, PPSV23, PCV15 - Part B; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Search by objective public record fields.

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Pneumococcal Adult-dose Ranging Immunization Study

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus/Diphtheria Vaccine

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

Pneumonia Vaccine in Aging HIV Positive Individuals

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

9-valent CRM 197 Pneumococcal

Immunogenicity of PCV-7 Vaccine in VLBW Infants

Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

Impact of Prevnar 13 on Ear Infections in Children

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)